NASDAQ:HEPA Hepion Pharmaceuticals (HEPA) Stock Price, News & Analysis → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free HEPA Stock Alerts $1.41 +0.12 (+9.30%) (As of 03:46 PM ET) Add Compare Share Share Today's Range$1.27▼$1.4450-Day Range$1.29▼$3.1752-Week Range$1.22▼$20.66Volume35,370 shsAverage Volume73,306 shsMarket Capitalization$7.71 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Hepion Pharmaceuticals alerts: Email Address Hepion Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy1.19% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.02Based on 10 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($11.43) to ($17.20) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.02 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Hepion Pharmaceuticals. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.19% of the float of Hepion Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverHepion Pharmaceuticals has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Hepion Pharmaceuticals has recently increased by 1.91%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldHepion Pharmaceuticals does not currently pay a dividend.Dividend GrowthHepion Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HEPA. Previous Next 1.1 News and Social Media Coverage News SentimentHepion Pharmaceuticals has a news sentiment score of -0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.33 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Hepion Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for HEPA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Hepion Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.95% of the stock of Hepion Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 17.24% of the stock of Hepion Pharmaceuticals is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Hepion Pharmaceuticals are expected to decrease in the coming year, from ($11.43) to ($17.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Hepion Pharmaceuticals is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Hepion Pharmaceuticals is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHepion Pharmaceuticals has a P/B Ratio of 1.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About Hepion Pharmaceuticals Stock (NASDAQ:HEPA)Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.Read More HEPA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HEPA Stock News HeadlinesApril 22, 2024 | finance.yahoo.comWhy Is Liver-Disease Drug Developer Hepion Pharmaceuticals Stock Trading Lower On Monday?April 22, 2024 | investorplace.comWhy Is Hepion Pharmaceuticals (HEPA) Stock Down 41% Today?April 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? April 22, 2024 | investorplace.comWhy Is Hepion Pharmaceuticals (HEPA) Stock Down 41% Today?April 21, 2024 | stockhouse.comHepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b 'ASCEND-NASH' TrialApril 20, 2024 | finanznachrichten.deHepion Pharmaceuticals, Inc.: Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b 'ASCEND-NASH' TrialApril 19, 2024 | marketwatch.comHepion Pharma to Wind-Down Phase 2b Ascend-NASH Trial, Cites Resource ConstraintsApril 19, 2024 | marketwatch.comHepion Pharma Shares Plunge 31% After Disclosing Plans to Wind Down TrialApril 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? April 19, 2024 | finance.yahoo.comHepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ TrialApril 19, 2024 | globenewswire.comHepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH' TrialApril 17, 2024 | msn.comHEPA Stock Earnings: Hepion Pharmaceuticals Beats EPS for Q4 2023April 14, 2024 | morningstar.comHepion Pharmaceuticals Inc HEPAMarch 24, 2024 | investing.comHepion Pharmaceuticals Inc (HEPA)March 6, 2024 | globenewswire.comHepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael PurcellFebruary 16, 2024 | finance.yahoo.comHepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross ProceedsFebruary 16, 2024 | globenewswire.comHepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross ProceedsJanuary 3, 2024 | finance.yahoo.comHepion Pharmaceuticals to Present at NASH-TAG 2024December 7, 2023 | finanznachrichten.deHepion Pharmaceuticals, Inc.: Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management ChangesDecember 7, 2023 | realmoney.thestreet.comHepion Pharmaceuticals downgraded to Hold from Buy at BrooklineDecember 7, 2023 | marketwatch.comHepion Sets Restructuring; To Explore Strategic OptionsDecember 7, 2023 | finance.yahoo.comHepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management ChangesNovember 28, 2023 | finance.yahoo.comHepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development SummitNovember 28, 2023 | msn.comHepion Pharmaceuticals says Wijngaard buys 5K shares in coNovember 13, 2023 | finance.yahoo.comHepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver DiseaseNovember 10, 2023 | benzinga.comHepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 'ALTITUDE-NASH' Liver Function Trial of RencofilstatNovember 10, 2023 | finance.yahoo.comHepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of RencofilstatSee More Headlines Receive HEPA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hepion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/16/2024Today4/26/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:HEPA CUSIPN/A CIK1583771 Webwww.hepionpharma.com Phone(732) 902-4000Fax732-902-4100Employees22Year Founded2013Profitability EPS (Most Recent Fiscal Year)($12.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-48,930,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-244.07% Return on Assets-151.60% Debt Debt-to-Equity RatioN/A Current Ratio3.31 Quick Ratio3.31 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.29 per share Price / Book1.06Miscellaneous Outstanding Shares5,470,000Free Float5,365,000Market Cap$7.49 million OptionableNo Data Beta1.54 Social Links 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. John T. Cavan (Age 66)Interim CEO & CFO Comp: $495.33kSharen PyatetskayaDirector of Investor RelationsDr. John Z. Sullivan-Bolyai (Age 76)Part-Time Consultant Dr. Stephen A. Harrison FACPM.D., Scientific Advisory Board Chair & Consultant Medical DirectorKey CompetitorsCyclerion TherapeuticsNASDAQ:CYCNVirios TherapeuticsNASDAQ:VIRIMolecular TemplatesNASDAQ:MTEMUniverse PharmaceuticalsNYSE:UPCNuCanaNASDAQ:NCNAView All CompetitorsInsiders & InstitutionsArmistice Capital LLCBought 20,393 shares on 2/13/2024Ownership: 9.631%Peter WijngaardBought 2,500 shares on 11/27/2023Total: $7,625.00 ($3.05/share)Peter WijngaardBought 2,500 shares on 11/24/2023Total: $7,725.00 ($3.09/share)Peter WijngaardBought 1,000 shares on 9/19/2023Total: $5,640.00 ($5.64/share)Robert T FosterBought 1,600 shares on 9/18/2023Total: $8,960.00 ($5.60/share)View All Insider TransactionsView All Institutional Transactions HEPA Stock Analysis - Frequently Asked Questions Should I buy or sell Hepion Pharmaceuticals stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Hepion Pharmaceuticals in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" HEPA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HEPA, but not buy additional shares or sell existing shares. View HEPA analyst ratings or view top-rated stocks. How have HEPA shares performed in 2024? Hepion Pharmaceuticals' stock was trading at $3.24 at the beginning of the year. Since then, HEPA stock has decreased by 56.5% and is now trading at $1.41. View the best growth stocks for 2024 here. Are investors shorting Hepion Pharmaceuticals? Hepion Pharmaceuticals saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 62,800 shares, an increase of 11.0% from the March 15th total of 56,600 shares. Based on an average trading volume of 76,600 shares, the short-interest ratio is presently 0.8 days. Approximately 1.5% of the shares of the company are short sold. View Hepion Pharmaceuticals' Short Interest. When is Hepion Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our HEPA earnings forecast. How were Hepion Pharmaceuticals' earnings last quarter? Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) released its quarterly earnings results on Tuesday, April, 16th. The company reported ($2.42) EPS for the quarter. When did Hepion Pharmaceuticals' stock split? Shares of Hepion Pharmaceuticals reverse split on Thursday, May 11th 2023. The 1-20 reverse split was announced on Thursday, May 11th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 11th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Hepion Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Hepion Pharmaceuticals investors own include Bausch Health Companies (BHC), Axsome Therapeutics (AXSM), Archrock (AROC), Alector (ALEC), AIM ImmunoTech (AIM), Applied Genetic Technologies (AGTC), Abbott Laboratories (ABT) and Ambev (ABEV). How do I buy shares of Hepion Pharmaceuticals? Shares of HEPA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:HEPA) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldMan Who Predicted 2008: “This Will be Worse.”AltimetryEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsTrump is sounding the alarmPreserve GoldJim Cramer’s “The Biggest Drug Ever”Behind the MarketsFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hepion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
